Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine PDF Print E-mail
Wednesday, 12 June 2013 20:55
Patients with systemic sclerosis effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers evaluated 19 patients with systemic sclerosis (SSc; mean age, 48 years; 84.2% women; 89.5% Caucasian; 53% limited SSc). Eleven patients had an active digital ulcer at baseline. Treprostinil diethanolamine sustained release (SR) was administered to patients with dose titration up to 4 mg twice daily.

Laser Doppler imaging quantified drug concentrations and perfusion, which were measured across 12 hours at 2 mg or 4 mg (or maximally tolerated) doses. Individual plasma concentration vs. time profiles using noncompartmental analysis methods determined pharmacokinetic parameters.

“Digital perfusion and skin temperature were modeled as a function of log-transformed drug concentration and other covariates by performing repeated measures analyses using random effects models,” the researchers wrote.

Sixteen patients completed the 8-week study. Approximately 3.6 hours after administration of treprostinil diethanolamine, peak plasma concentrations reached means of 1,176 pg/mL and 2,107 pg/mL for 2-mg and 4-mg doses, respectively. Overall exposure (AUC from 0 to 12 hours) was linear between doses and observed at 7,187 hr*pg/mL for 2-mg and 12,992 hr*pg/mL for 4-mg doses. Log-transformed plasma at the 4-mg dose had a positive association with perfusion (P=.015) and digital skin temperature (P=.013).

The most common adverse events were headache (89%), diarrhea (47%) and nausea (42%), which were similar to those seen with prostacyclin analogs. No serious adverse events or deaths were reported.

“Currently prostacyclin analogs are administered via intravenous or subcutaneous routes in [systemic sclerosis] patients with vascular complications,” the researchers concluded. “Our data show that oral SR formulation of treprostinil diethanolamine was effectively absorbed in patients with SSc, was associated with improved cutaneous perfusion and temperature with short-term treatment, and may provide a new therapeutic option for Raynaud’s phenomenon and peripheral vascular disease of SSc.”

Source: Helio
 
More articles :

» Comprehensive Report on the Global State of Autoimmune Diseases Released

A groundbreaking new report from the (AARDA), examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit:  The Global State...

» Rare Disease Research Teams Receive Over $17m In Funding

(CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while...

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» The Clinical Relevance of Autoantibodies in Scleroderma

Khanh T Ho and John D ReveillePublished: 12 February 2003Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628)© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)Scleroderma (systemic sclerosis) is associated with several...

» Central Nervous System Manifestations In Scleroderma

We at the believe that knowledge is indeed, power. It was this belief that became the primary motivation for the creation of our website. It was meant to empower all patients to take control of the disease through news and informative articles, and...

» June Is Scleroderma Awareness Month!

The month of June is Scleroderma Awareness Month around the world, and would like to encourage each and everyone of you, to become advocates by raising awareness and educating others about this often progressive, autoimmune connective tissue disease...